Ureteral Metastasis: Uncommon Manifestation in Prostate Cancer.
Ureteral metastasis from a primary prostate cancer is a rare event in the initial diagnosis and progression of prostate cancer. We report here the case of a 72- year-old patient who was treated for castration-resistant metastatic prostate cancer involving bone, intra-abdominal lymph nodes, bilateral adrenal glands, and a small distal ureteral lesion with left hydronephrosis considered in remission, with a luteinizing hormone-releasing hormone analog plus abiraterone acetate (AA) and prednisone after initial docetaxel plus prednisone chemotherapy. After an episode of acute left flank pain, the previous left distal intraluminal ureteral mass appeared increased in volume on computed tomographic scan and was compatible with either a metastasis from prostate cancer, transitional cell carcinoma of the ureter, or a collision tumor. After left nephroureterectomy (NU), the mass was confirmed to be of prostatic origin on histopathological examination and the only site of metastatic progression of prostate cancer. Abdominal CT-scan and the operative specimen of the NU showed no direct extension of the abdominal lymph nodes into the ureteral lesion. We speculate that this unique ureteral prostate cancer metastasis was the result of hematogenic spread of prostate cancer, although microscopic spread through the lymphatic system could not be excluded. The transient anti-tumor effect of AA plus prednisone at the level of ureteral metastasis, as far as we are aware of, has never been documented before.
Department of Medical Oncology, Oncology Center UZ Brussels, Brussels, Belgium denis.schallier@uzbrussel.be.
Denis
D
Schallier
Department of Urology, General Municipal Hospital Aalst, Aalst, Belgium.
Bernard
B
Rappe
Department of Pathology, General Municipal Hospital Aalst, Aalst, Belgium.
Marilyn
M
Carprieaux
Department of Radiology, Oncology Center UZ Brussels, Brussels, Belgium.
Frederik
F
Vandenbroucke
D000069501:Abiraterone Acetate / Q000008:administration & dosage; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D000077143:Docetaxel; D006801:Humans; D008297:Male; D011241:Prednisone / Q000008:administration & dosage; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood; D064129:Prostatic Neoplasms, Castration-Resistant / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D043823:Taxoids / Q000008:administration & dosage; D014516:Ureteral Neoplasms / Q000139:chemically induced / Q000556:secondary* / Q000601:surgery
D043823:Taxoids; D000077143:Docetaxel; D017430:Prostate-Specific Antigen; D000069501:Abiraterone Acetate; D011241:Prednisone
Prostate cancer; abiraterone acetate; ureteral metastasis